Focus Advisor Solutions LLC grew its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,585 shares of the biotechnology company’s stock after purchasing an additional 2,896 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Biogen were worth $2,391,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Bell Investment Advisors Inc bought a new stake in Biogen during the 2nd quarter worth about $27,000. Align Financial LLC raised its stake in shares of Biogen by 339.3% in the third quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 95 shares during the last quarter. Provenance Wealth Advisors LLC bought a new position in shares of Biogen in the third quarter worth about $29,000. Canton Hathaway LLC acquired a new position in shares of Biogen during the third quarter worth approximately $31,000. Finally, Financial Freedom LLC acquired a new position in shares of Biogen during the third quarter worth approximately $34,000. Institutional investors own 87.93% of the company’s stock.
Analyst Ratings Changes
Several research firms have issued reports on BIIB. Mizuho set a $271.00 price objective on Biogen in a report on Friday. Needham & Company LLC restated a “buy” rating on shares of Biogen in a research report on Wednesday. Bank of America boosted their target price on Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Citigroup reaffirmed a “neutral” rating on shares of Biogen in a research note on Wednesday, October 28th. Finally, Argus upgraded Biogen from a “hold” rating to a “buy” rating and set a $280.00 price target on the stock in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.45.
Recent Biogen Headlines
These are some of the BIIB headlines that stood out recently:
- Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
- Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article
- Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article
Biogen Price Performance
NASDAQ BIIB opened at $249.59 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. The stock has a market cap of $36.89 billion, a price-to-earnings ratio of 106.66, a PEG ratio of 2.83 and a beta of 0.10. The business has a 50 day simple moving average of $236.83 and a 200 day simple moving average of $206.86. Biogen Inc. has a 52-week low of $160.36 and a 52-week high of $261.00.
Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter in the prior year, the company earned $4.81 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. Analysts anticipate that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.
Biogen Company Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Read More
- Five stocks we like better than Biogen
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
